About Bright Minds Biosciences
Bright Minds Biosciences is a private company based in New York, New York. It has reported $1,998,540 raised in 12 offerings on Form D since October 2020. Its chief executive is Ian McDONALD.
Funding Rounds (SEC Form D)
| First sale | Filed with SEC | Amount sold | Investors | Avg. check | Terms | Filing |
|---|---|---|---|---|---|---|
| Mar 22, 2024 | May 3, 2024 | $0of $54,160 target | 2 | $0 | Equity, Options, Securities on exercise, Share purchase options ("Options") granted pursuant to the Common Stock Option Plan of the Company. Each Option is exercisable to purchase one common share of the Company at C$1.84 for a period of 5 years from the date of grant.Rule 506(b) | Form D ↗ |
| Sep 6, 2022 | Sep 14, 2022 | $0of $149K target | 1 | $0 | Options, Securities on exerciseRule 506(b) | Form D ↗ |
| Aug 30, 2022 | Sep 1, 2022 | $0of $220K target | 1 | $0 | Equity, Options, Securities on exercise, Compensation Warrants, each exercisable into units of the Issuer ("Units"). Each Unit consisting of one common share and one common share purchase warrant ("Warrant").Rule 506(b) | Form D ↗ |
| Feb 11, 2022 | May 3, 2022 | $82,667fully sold | 1 | $82,667 | Equity, Options, Securities on exercise, Restricted Share Units (RSUs) convertible into shares upon settlement of the RSU. The RSUs will vest over a period of 4 years.Rule 506(b) | Form D ↗ |
| Feb 4, 2022 | May 3, 2022 | $59,765fully sold | 1 | $59,765 | Equity, Options, Securities on exercise, Restricted Share Units (RSUs) convertible into shares upon settlement of the RSU. The RSUs will vest over a period of 4 years.Rule 506(b) | Form D ↗ |
| Jun 15, 2021 | Jun 25, 2021 | $0of $623K target | 1 | $0 | Options, Securities on exerciseRule 506(b) | Form D ↗ |
| Apr 29, 2021 | May 4, 2021 | $299,815fully sold | 1 | $299K | EquityRule 506(b) | Form D ↗ |
| Mar 17, 2021 | Mar 23, 2021 | $516,175of $838K target | 1 | $516K | Equity, Options, Securities on exercise, Units, each unit is comprised of one common share and one-half of one warrant. Each whole warrant is exercisable into a share at C$9.46 until March 17, 2024, subject to acceleration.Rule 506(b) | Form D ↗ |
| Nov 2, 2020 | Nov 17, 2020 | $1,602fully sold | 17 | $94 | Equity, Options, Securities on exercise, Special Warrants, automatically convertible without payment of additional consideration, into common shares upon satisfaction of certain escrow release conditions.Rule 506(b) | Form D ↗ |
| Nov 2, 2020 | Nov 17, 2020 | $680,470fully sold | 12 | $56,706 | EquityRule 506(b) | Form D ↗ |
| Sep 18, 2020 | Oct 7, 2020 | $218,040fully sold | 1 | $218K | Equity, Options, Securities on exercise, Restricted Share Units (RSUs) convertible into shares upon settlement of the RSU. The RSUs will vest over a period of 4 years.Rule 506(b) | Form D ↗ |
| Jul 23, 2020 | Oct 6, 2020 | $140,006of $280K target | 1 | $140K | Equity, Options, Securities on exercise, Options exercisable into shares for a period of 5 years and Restricted Share Units (RSUs) exercisable into shares, of which RSUs will vest over a period of 4 years.Rule 506(b) | Form D ↗ |
| Total, 12 offerings | $1,998,540 | |||||
First sale is the date the first investor in the offering committed to invest. Companies must file Form D within 15 days of that date, so filing dates run later.
Leadership Team
Executive officers and directors listed on Bright Minds Biosciences's Form D filed May 3, 2024.
Earlier filings also listed Revati Shreeniwas (chief medical officer, last listed Sep 2022), Douglas Williamson (director, last listed Sep 2022), Alan Kozikowski (director, last listed Sep 2022), Revati Sheeniwas (executive officer, last listed May 2022), Gideon Shapiro (executive officer, last listed May 2022) and Emer Leahy (director, last listed Jun 2021).